For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development | 148,024 | 144,101 | ||
| General and administrative | 32,863 | 48,849 | ||
| Total operating expenses | 180,887 | 192,950 | ||
| Loss from operations | -180,887 | -192,950 | ||
| Interest income and other, net | 16,376 | 25,490 | ||
| Loss before income taxes | -164,511 | -167,460 | ||
| Income tax benefit (expense) | -6,162 | 925 | ||
| Net loss | -158,349 | -168,385 | ||
| Unrealized (loss) gain on available-for-sale investments | -59 | 26 | ||
| Comprehensive loss | -158,408 | -168,359 | ||
| Basic EPS | -1.94 | -2 | ||
| Diluted EPS | -1.94 | -2 | ||
| Basic Average Shares | 81,495,352 | 84,264,715 | ||
| Diluted Average Shares | 81,495,352 | 84,264,715 | ||
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)